Factors associated with stillbirth in women with diabetes by , et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factors associated with stillbirth in women with diabetes
Citation for published version:
SDRN Epidemiology Group and Scottish Diabetes Group Pregnancy subgroup , Mackin, ST, Nelson, SM,
Wild, S, Colhoun, H, Wood, R & Lindsay, R 2019, 'Factors associated with stillbirth in women with diabetes',
Diabetologia. https://doi.org/10.1007/s00125-019-4943-9
Digital Object Identifier (DOI):
10.1007/s00125-019-4943-9
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Diabetologia
Publisher Rights Statement:
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:/
/creativecommons.org /licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 02. Jan. 2020
ARTICLE
Factors associated with stillbirth in women with diabetes
Sharon T. Mackin1 & Scott M. Nelson2 & Sarah H. Wild3 & Helen M. Colhoun4 & Rachael Wood5 & Robert S. Lindsay1 & on
behalf of the SDRN Epidemiology Group and Scottish Diabetes Group Pregnancy subgroup
Received: 16 January 2019 /Accepted: 20 May 2019
# The Author(s) 2019
Abstract
Aims/hypothesis Stillbirth risk is increased in pregnancy complicated by diabetes. Fear of stillbirth has major influence on
obstetric management, particularly timing of delivery. We analysed population-level data from Scotland to describe timing of
stillbirths in women with diabetes and associated risk factors.
Methods A retrospective cohort of singleton deliveries to mothers with type 1 (n = 3778) and type 2 diabetes (n = 1614) from 1
April 1998 to 30 June 2016 was analysed using linked routine care datasets. Maternal and fetal characteristics, HbA1c data and
delivery timing were compared between stillborn and liveborn groups.
Results Stillbirth rates were 16.1 (95%CI 12.4, 20.8) and 22.9 (95%CI 16.4, 31.8) per 1000 births in women with type 1 (n = 61)
and type 2 diabetes (n = 37), respectively. In women with type 1 diabetes, higher HbA1c before pregnancy (OR 1.03 [95% CI
1.01, 1.04]; p = 0.0003) and in later pregnancy (OR 1.06 [95%CI 1.04, 1.08]; p < 0.0001) were associated with stillbirth, while in
women with type 2 diabetes, higher maternal BMI (OR 1.07 [95% CI 1.01, 1.14]; p = 0.02) and pre-pregnancy HbA1c (OR 1.02
[95% CI 1.00, 1.04]; p = 0.016) were associated with stillbirth. Risk was highest in infants with birthweights <10th centile
(sixfold higher born to women with type 1 diabetes [n = 5 stillbirths, 67 livebirths]; threefold higher for women with type 2
diabetes [n = 4 stillbirths, 78 livebirths]) compared with those in the 10th–90th centile (n = 20 stillbirths, 1685 livebirths). Risk
was twofold higher in infants with birthweights >95th centile born to women with type 2 diabetes (n = 15 stillbirths, 402
livebirths). A high proportion of stillborn infants were male among mothers with type 2 diabetes (81.1% vs 50.5% livebirths,
p = 0.0002). A third of stillbirths occurred at term, with highest rates in the 38th week (7.0 [95% CI 3.7, 12.9] per 1000 ongoing
pregnancies) among mothers with type 1 diabetes and in the 39th week (9.3 [95% CI 2.4, 29.2]) for type 2 diabetes.
Conclusions/interpretation Maternal blood glucose levels and BMI are important modifiable risk factors for stillbirth in diabetes.
Babies at extremes of weight centiles are at most risk. Many stillbirths occur at term and could potentially be prevented by change
in routine care and delivery policies.
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Abbreviations
IUGR Intrauterine growth restriction
LGA Large for gestational age
RDS Respiratory distress syndrome
SCI-Diabetes Scottish Care Information-Diabetes
SGA Small for gestational age
SIMD Scottish Index of Multiple Deprivation
SMR02 Scottish Morbidity Record 02
Introduction
Mothers with pregestational diabetes are at 4–5-fold in-
creased risk of stillbirth [1], with data from our and
other populations showing no improvement in recent
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years [1, 2]. This contrasts with decreasing stillbirth
rates seen in the general obstetric population [1].
Maternal obesity, advanced maternal age and smoking
are important modifiable risk factors for stillbirth in
the general obstetric population [3, 4]. Fetal growth is
also important, with growth-restricted pregnancies hav-
ing the highest risk [3]. Data on pregnancies complicat-
ed by diabetes are more limited. Suboptimal maternal
blood glucose levels even at minimal levels, presence
of microvascular complications and poor preparation
for pregnancy are associated with stillbirth [5, 6].
Other traditional risk factors seen in the general obstetric
population are less well documented in diabetes.
Prevention of stillbirth underpins part of the clinical ra-
tionale for obstetric intervention in diabetes, particularly
around timing of delivery. While we lack predictive
models, presence of risk factors may guide obstetricians
to earlier delivery, which is appropriate in many cases
but associated with neonatal morbidity [7]. We therefore
analysed national data from all deliveries to mothers
with pregestational diabetes in Scotland over an 18 year
period, to better define maternal and fetal characteristics
associated with stillbirth. Timing of stillbirth was also
analysed to identify potential for population-based strat-
egies around routine delivery.
Methods
Data sources
As previously described [1], we linked data from maternity
records in the Scottish Morbidity Record 02 (SMR02) data-
base and the national diabetes database, Scottish Care
Information-Diabetes (SCI-Diabetes). SMR02 contains
clinical information on all obstetric inpatient episodes
across Scotland including maternal and infant demo-
graphics, obstetric complications and delivery details.
Quality assurance procedures have shown >90% comple-
tion and accuracy for data [8]. SCI-Diabetes contains pa-
tient demographics and clinical information on diabetes di-
agnosis, presence of complications and management.
National data capture is excellent, with 99.5% of the
Scottish population with diabetes included from 2004 on-
wards [9]. Diabetes diagnosis is entered onto SCI-Diabetes
by individual clinical teams, and correlates with inpatient
records in greater than 99% of cases [9]. For this study, type
of diabetes was further refined by algorithm based on pre-
scription history and age of diagnosis. Type 1 was
reclassified as type 2 diabetes if there was more than 1 year
without diabetes medications prescribed or treatment with
oral hypoglycaemic agents only. Type 2 diabetes was
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reclassified as type 1 if diabetes was diagnosed under
30 years of age and initiated on insulin therapy within 1 year
of diagnosis.
Episodes that resulted in the delivery of an infant at or
beyond 24 weeks of gestation from 1 April 1998 to 30
June 2016 were identified from SMR02. Linkage with SCI-
Diabetes identified mothers diagnosed with type 1 or type 2
diabetes predating delivery. Mothers with other diabetes diag-
noses were excluded (n = 145). Analysis was restricted to sin-
gleton births only.
Definitions
In keeping with the legal definition set out in the 1992 amend-
ment of the Births and Deaths Registration (Scotland) Act
1965 [10], stillbirth was defined as the birth of an infant at
or after 24 weeks of gestation, who at the time of delivery did
not breathe or show signs of life. Gestational age has been
calculated from ultrasound scanning in the first half of preg-
nancy in >95% of pregnancies since the 1990s [11].
Birthweight z score taking into account infant gestation at
delivery, sex and parity was calculated using a reference pop-
ulation of all Scottish births between 1998 and 2003 [12].
Large for gestational age (LGA) describes infants whose
corrected birthweights were above the 90th centile, while
small for gestational age (SGA) included those below the
10th centile.
The Scottish Index of Multiple Deprivation (SIMD) 2012
score was used as a national standard measure of deprivation
[13]. SIMD scores are calculated at small area (data zone) level
based onmultiple indicators ofmaterial deprivation, with wom-
en allocated to a score based on their postcode at time of de-
livery. Scores range from 0.89 to 89.89, with higher numbers
reflecting residence in an area of higher material deprivation.
HbA1c data are presented according to stages of pregnancy.
The pre-pregnancy period was defined as 6 months preceding
estimated conception date, and HbA1c data were collected for
the latest entry within that time. Conception date was calcu-
lated from gestational age and date of delivery. First trimester
was defined as days 1–90 of pregnancy (up to week 12 + 6
days), trimester two as days 91–188 (week 13 + 0 days to
week 26 + 6 days and trimester three from day 189 to delivery
(week 27 onwards).
Mother’s BMI was available from routine diabetes clinic
appointments (outwith pregnancy) and included as the last
BMI within 6 months before pregnancy.
Healthcare provision in Scotland is divided into local
health boards, defined by 14 distinct geographical areas [14].
We examined outcomes by health board of delivery and de-
livering hospital size, defined according to the mean number
of deliveries of mothers with diabetes performed per annum
(grouped as less than 5, 5 to 9, 10 to 19, 20 to 29, and 30 or
greater deliveries). Very small units delivering under five
women across the entire course of the study were not included.
This represented 126 deliveries and under 1.8% of all data.
Data for health boards are presented anonymised (A to K).
Statistics
Data analysis was performed using Statistical Analysis
Software (SAS) v.9.4 (Cary, NC, USA). Crude stillbirth rates
are presented with a denominator of ongoing pregnancies at
that gestational week. Risk factors and pregnancy outcomes
are presented according to diabetes diagnosis for those in still-
birth and livebirth groups as means and SDs, or frequencies,
as appropriate. As women may have had more than one preg-
nancy (range 1–8 with 67% of women having a single preg-
nancy and 94% one or two pregnancies), comparison between
groups was assessed using a generalised mixed model with a
term for the mother incorporated as a random effect.
Differences in outcomes between health board and hospital
unit size were analysed using logistic regression or general
linear model with additional terms for year of delivery, depri-
vation score, maternal age, smoking and diabetes duration as
appropriate. Due to low absolute numbers, effect of health
board area of delivery and unit size on stillbirth rates was
calculated from data combining type 1 and type 2 deliveries
together, but including a term for type of diabetes. For analysis
of stillbirth, two small island and one mainland health board
were excluded due to low number of deliveries (<5 per
annum). For analysis of the association of health board area
and size with birthweight and gestational age at delivery, these
were included. Statistical significance was assumed where
p < 0.05.
The Caldicott Guardians of all Health Boards in Scotland
and the Privacy Advisory Committee of the Information
Services Division (ISD) of NHS Scotland approved database
access and linkage. Ethical approvals were provided by the
national multicentre research ethics committee. Data were
accessed in a pseudonymised format.
Results
There were 5621 pregnancies in mothers with diabetes, of
which 229 were excluded for reasons including missing ges-
tational age at delivery (n = 7), missing sex of infant (n = 3),
delivery before 24 weeks of gestation (n = 5), diabetes diag-
nosis other than type 1 or type 2 (n = 145) or twin pregnancy
(n = 74). Exclusions could have been in more than one
category.
The remaining 5392 singleton babies (3778 offspring of
mothers with type 1 diabetes, 1614 offspring of mothers with
type 2 diabetes) were born to 3847 mothers (2582 mothers
with type 1 diabetes, 1265 mothers with type 2 diabetes).
Stillbirth rates were 16.1 per 1000 births (95% CI 12.4,
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20.8) in type 1 diabetes (n = 61) and 22.9 per 1000 births (95%
CI 16.4, 31.8) in type 2 diabetes (n = 37). Stillbirth rates did
not change with time in type 1 diabetes. There was a very
small reduction with time in type 2 diabetes (p = 0.02).
Type 1 diabetes
Distributions of age, parity, smoking rates and deprivation
scores were similar in mothers regardless of whether the preg-
nancy ended in stillbirth or livebirth (Table 1). Duration of
diabetes was lower in the stillbirth group, as was pre-
pregnancy BMI (Table 1).
HbA1c was recorded at each stage of pregnancy in 50–60%
of cases (Fig. 1). Stillbirth rates were similar in womenwith an
available pre-pregnancy HbA1c measure to those without
(1.6% both, p = 0.9), despite higher levels of deprivation and
smoking (26.1% vs 17.0%) in those without a pre-pregnancy
HbA1c measurement (electronic supplementary material
[ESM] Table 1). Overall, one in five women achieved pre-
pregnancy glycaemic targets (<53mmol/mol [7%]), with low-
er rates in the stillbirth group (Table 1). Mean pre-pregnancy
HbA1c was 11 mmol/mol (1%) higher in pregnancies ending
in stillbirth (p = 0.0002). Glycaemic control improved from
pre-pregnancy across successive trimesters in both stillborn
and liveborn groups, but with the stillborn group maintaining
a similar relative level of hyperglycaemia compared with the
liveborn group at all points (Fig. 1).
Stillborn infants were born 2.8 weeks earlier than liveborn
infants (Table 1). Stillbirths occurred between weeks 24 and
38, with over a third (38%) at term (Fig. 2), compared with
63% of livebirths occurring at term. Stillbirth rates (expressed
per week of pregnancy) were highest in the 37th and 38th
weeks at 5.1 (95% CI 2.8, 9.1) and 7.0 (95% CI 3.7, 12.9)
per 1000 ongoing pregnancies, respectively (Fig. 2). There
were no stillbirths after 38 weeks, and only 11% of all deliv-
eries occurred beyond this.
HbA1c, birthweight and stillbirth risk Stillborn infants had
similar corrected birthweights to liveborn infants, with
birthweight z scores 1.38 and 1.37, respectively (Table 1).
Over half of babies (52% combined live and stillborn) born
to mothers with type 1 diabetes were LGA, of which the ma-
jority (78%) had birthweights above the 95th centile (ESM
Table 2). Higher birthweight was related to higher HbA1c.
Mean birthweight z scores for this combined group were 0.9
(0.12) SD higher than the reference population in the sub-
group of women in the lowest quartiles for HbA1c pre-
pregnancy (<52 mmol/mol [6.9%]) and in the third trimester
(<42 mmol/mol [6.0%]), increasing to 1.73 (0.09) SD for
those in the highest quartiles (>76 mmol/mol [9.1%] pre-
pregnancy and > 56 mmol/mol [7.3%] third trimester) (ESM
Table 3). SGA infants had sixfold higher stillbirth rates than
birthweight appropriate for gestational age infants (ESM
Table 2). There was a significant non-linear relationship of
birthweight z score and stillbirth (p = 0.002). When
categorised as in ESM Table 2, there was a significant effect
of birthweight category (p = 0.005) and SGA vs the reference
category in particular.
Table 1 Maternal and neonatal factors associated with stillbirth according to infant vital status and type of diabetes
Factor Type 1 diabetes (n = 3778 babies to 2582
mothers)
Type 2 diabetes (n = 1614 babies to 1265
mothers)
Stillbirth (n = 61) Livebirth (n = 3717) Stillbirth (n = 37) Livebirth (n = 1577)
Maternal age at delivery, years 29.1 (5.3) 29.8 (5.7) 33.8 (6.0) 33.2 (5.6)
SIMD score 25.4 (16.4) 23.5 (17.1) 28.4 (19.1) 28.0 (18.1)
Duration of diabetes, years 11.4 (9.2)* 14.1 (8.4) 4.4 (4.0) 4.2 (4.1)
Nulliparous. % 55.7 50.0 16.7 31.3
Maternal smoking, % 25.5 20.4 30.3 21.0
Pre-pregnancy maternal BMI 24.8 (4.9)* 26.3 (4.9) 38.2 (6.4)* 33.9 (7.1)
Preconception HbA1c below 53 mmol/mol (7%)
a, % 7.9 (3 of 38) 19.6 (438 of 2236) 28.6 (4 of 14) 47.6 (380 of 799)
Male fetus, % 54.1 49.4 81.1*** 50.5
Gestational age delivery, weeks 33.8 (4.1)*** 36.6 (2.2) 33.7 (4.7) *** 37.2 (2.3)
Birthweight z score 1.38 (1.69) 1.37 (1.30) 1.08 (1.82) 0.83 (1.36)
Values are presented as percentage of group, or as mean (SD)
Missing values (n): Parity: 40 in type 1, 13 in type 2; maternal smoking: 294 in type 1, 128 in type 2; pre-pregnancy BMI: 1302 in type 1, 776 in type 2;
preconception HbA1c: 1427 in type 1, 801 in type 2; birthweight z score: 50 in type 1, 13 in type 2
a Scottish Intercollegiate Guidelines Network (SIGN) recommended target HbA1c< 53 mmol/mol pre-pregnancy
*p < 0.05, ***p < 0.001 in generalised mixed models for stillbirth vs livebirth
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Type 2 diabetes
Mothers who had a stillbirth had higher mean pre-pregnancy
BMI than mothers delivering a live infant (p = 0.01, Table 1)
and with a non-significant trend to higher parity (p = 0.06).
Stillborn infants were more likely to be male (p = 0.0007).
Smoking, deprivation score and duration of diabetes were
similar between groups (Table 1). HbA1c was documented at
each gestational period in approximately 50% of cases (Fig.
1). There was no difference in stillbirth rates in those with an
available pre-pregnancy HbA1c vs those without (2.1% vs
2.5%, respectively; p = 0.6). Almost half of women achieved
pre-conceptual targets (<53 mmol/mol [7%]), with lower rates
in the stillbirth group. There was no association between ges-
tational blood glucose level and stillbirth (Fig. 1) but precon-
ception HbA1c was 12 mmol/mol (1.1%) higher in the still-
birth group (p = 0.01).
In type 2 diabetes, stillborn infants were delivered over
3 weeks earlier than liveborn infants (p < 0.0001) (Table 1).
Stillbirth occurred in low frequency across all gestations from
24 weeks (Fig. 2), with 68% occurring preterm (Fig. 2) com-
pared with 24% of livebirths occurring preterm. Stillbirth rates
were highest in the 39th week at 9.3 (95% CI 2.4, 29.2) per
1000 ongoing pregnancies (Fig. 2).
HbA1c, birthweight and stillbirth riskMean birthweights were
similar between live and stillborn infants (Table 1). Stillbirth
odds were highest amongst infants with birthweights <10th
centile (threefold) and > 95th centile (2.2-fold) (ESMTable 2).
There was a significant non-linear relationship of birthweight
z score and stillbirth (p = 0.007) and, when categorised as in
ESM Table 2, there was a significant effect of birthweight
category (p = 0.04), with suggestion of increased risk for both
SGA and birthweight percentile >95th. Similar to type 1,
babies (live and stillborn) born to mothers with HbA1c in the
lowest pre-pregnancy and third trimester quartiles were 0.39
(0.13) SD heavier than the reference population. This in-
creased to 1.79 (0.26) SD for those with HbA1c in the highest
pre-pregnancy and third trimester quartiles (ESM Table 3).
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Fig. 1 Mean HbA1c according to stage of pregnancy and vital status of
infant in women with (a) type 1 diabetes and (b) type 2 diabetes. Blue
diamond, mean HbA1c in livebirths; red diamond, mean HbA1c in still-
births. Error bars show SD. *p < 0.05, ***p < 0.01 for stillbirth vs
livebirth in the same diabetes group at the same pregnancy stage using
a generalised mixed model with mother as random effect. Number of
available HbA1c values: pre-pregnancy: 2313 (62%) livebirths and 38
(63%) stillbirths in women with type 1 diabetes; 796 (50%) livebirths
and 17 (46%) stillbirths in women with type 2 diabetes; first trimester:
2156 (58%) livebirths and 30 (49%) stillbirths in women with type 1
diabetes; 785 (50%) livebirths and 15 (41%) stillbirths in women with
type 2 diabetes; second trimester: 2119 (57%) livebirths and 29 (48%)
stillbirths in women with type 1 diabetes; 775 (49%) livebirths and 16
(43%) stillbirths in women with type 2 diabetes; third trimester: 1933
(52%) livebirths and 27 (44%) stillbirths in women with type 1 diabetes;
782 (50%) livebirths and 11 (30%) stillbirths in women with type 2
diabetes
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Fig. 2 Stillbirth rate (per 1000 ongoing pregnancies) in women with (a)
type 1 diabetes and (b) type 2 diabetes according to gestational age at
delivery. Red bars, crude stillbirth rates (per 1000 ongoing pregnancies)
on the y-axis; blue line, absolute number of live deliveries on the second-
ary y-axis
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Risk factor effect estimation in stillbirth
In type 1 diabetes, univariate models suggested that shorter
diabetes duration (OR 0.96 [95% CI 0.93, 0.99]; p = 0.01)
and lower BMI (OR 0.92 [95% CI 0.86, 0.99]; p = 0.04) were
weakly associated with stillbirth. There were significant asso-
ciations between stillbirth and higher HbA1c pre-pregnancy
(OR 1.03 [95% CI 1.01, 1.04]; p = 0.0003) and in each trimes-
ter (OR 1.04 [95%CI 1.02, 1.05], 1.05 [95%CI 1.03, 1.07] and
1.06 [95% CI 1.04, 1.08] in first, second and third trimesters,
respectively; all p < 0.0001). These effects remained in models
adjusted for maternal age, SIMD and diabetes duration.
For type 2 diabetes, univariate models showed that higher
BMI (OR 1.07 [95% CI 1.01, 1.14]; p= 0.02) and higher pre-
pregnancyHbA1c (OR 1.02 [95%CI 1.00, 1.04]; p= 0.016) were
associated with stillbirth. In contrast to type 1 diabetes, HbA1c
later in pregnancy was not associated. These effects remained
when adjusted for maternal age, SIMD and diabetes duration.
For type 1 diabetes, we further explored whether associa-
tions between HbA1c and stillbirth varied by timing of HbA1c.
Unsurprisingly, HbA1c at various stages of pregnancy was
highly correlated (ESM Table 4). In models including mater-
nal age, diabetes duration, deprivation score, and pre-
pregnancy and third trimester HbA1c (n = 1382 with all vari-
ables), only third trimester HbA1c remained significantly as-
sociated with stillbirth (OR 1.05 [95% CI 1.02, 1.08]; p =
0.0008). The effect of HbA1c pre-pregnancy was attenuated
(OR 1.02 [95% CI 0.99, 1.04]; p = 0.08). Third trimester
HbA1c did not have a significantly greater effect than pre-
pregnancy HbA1c (p = 0.12) on stillbirth but analysis was lim-
ited by low numbers of women with both HbA1c measures.
For type 2 diabetes, the effect of BMI appeared in-
dependent of pre-pregnancy HbA1c, with both remaining
associated with stillbirth (OR 1.09 [95% CI 1.02, 1.17];
p = 0.01 and 1.03 [95% CI 1.01, 1.05]; p = 0.006, re-
spectively) in models including both factors, maternal
age, diabetes duration and deprivation score (n = 594
with all values).
Variation by region and unit size
There were no significant differences in stillbirth rates by
health board area of delivery (p = 0.60) or by hospital unit size
(p = 0.39). Regional differences in gestational age at delivery
were observed for type 1 (range 33.4 ± 1.6 to 36.9 ± 0.2weeks,
p < 0.0001) and type 2 diabetes (range 36.4 ± 0.3 to 37.8 ±
0.2 weeks, p = 0.006). This appeared partly driven by earlier
delivery in very small boards, but remained significant after
exclusion of these in type 1 (range 36.1 ± 0.1 to 36.9 ±
0.2 weeks, p < 0.0001) and type 2 diabetes (range 36.5 ± 0.3
to 37.8 ± 0.2 weeks, p = 0.007) (ESM Fig. 1). Babies born at
the largest units were delivered 4 days earlier than those de-
livering 10–19 mothers with diabetes per annum in type 1
(p = 0.002), but with no difference in type 2 diabetes. Mean
birthweight z score in type 2 diabetes varied across health
boards (p < 0.0001) (ESM Fig. 1), but not in type 1 diabetes
(p = 0.05). Birthweight z score did not vary by hospital unit
size in type 1 (p = 0.20) or type 2 diabetes (p = 0.15) in models
including smoking (lower in smokers), year of delivery (small
increase with time), maternal age at delivery (reduced with
age), diabetes duration (increased with duration type 2 diabe-
tes) and deprivation score (similar in type 2 diabetes, lower
with higher SIMD in type 1 diabetes).
Discussion
We have examined risk factors for stillbirth in a large popula-
tion of mothers with diabetes. In keeping with other studies,
we find that maternal blood glucose level is the keymodifiable
risk factor for adverse perinatal outcomes [6, 15, 16]. Women
with type 1 diabetes who suffer a stillbirth have higher mean
HbA1c levels at all stages of pregnancy, although blood glu-
cose level improves in both groups over the course of preg-
nancy. At the same time, there is large overlap in HbA1c values
between live and stillborn groups. The pattern of blood glu-
cose levels in women with type 2 diabetes in relation to still-
birth appears somewhat different. Pre-pregnancy HbA1c ap-
pears a more important predictor in type 2 diabetes, and un-
expectedly there was no independent association in later preg-
nancy. The number of stillbirths in this group is small, how-
ever, and the findings should be interpreted with caution. An
important clinical correlate is that pre-pregnancy counselling
including glycaemic control may be particularly important to
address in women with type 2 diabetes but uptake is generally
lower than in type 1 diabetes [17]. Overall efforts to improve
blood glucose levels before and during pregnancy remain
central.
Despite lower blood glucose levels, mothers with type 2
diabetes had higher stillbirth rates than mothers with type 1
diabetes, in keeping with other reports [18, 19]. Maternal BMI
was associated with stillbirth in this group. Maternal obesity is
an independent risk factor for stillbirth, contributing to higher
rates of preeclampsia, congenital anomalies and fetal over-
growth [20, 21]. Gestational weight gain would be of interest,
with excessive gain conferring additional risk, but we lack
data on late pregnancy weight to explore this further
[22–24]. Other factors known to increase stillbirth include
advancing maternal age [4], nulliparity, maternal smoking
and social deprivation [3, 4]. While they were not formally
statistically significant in their effects on stillbirth, we ac-
knowledge their importance more widely in pregnancy
outcomes.
The aetiology of stillbirth is still often unclear and we do
not have specific information on causes in this cohort. In
diabetes, at least some cases will reflect underlying congenital
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anomaly, the risk of which is associated with early pregnancy
blood glucose levels [25]. However, in keeping with other
studies, we expect that most stillbirths were unrelated to con-
genital anomalies, and instead caused by metabolic effects on
fetal growth and placental function [26, 27].
Is it possible to predict those babies most at risk? Babies at
the extremes of centiles for growth are known to have an
increased risk of stillbirth [28]. In the general obstetric popu-
lation, intrauterine growth restriction (IUGR) is the strongest
indicator of stillbirth risk, increasing 4.0-fold if detected ante-
natally, and 8.0-fold if undetected [3]. In our data, absolute
risk of stillbirth was highest in SGA infants, particularly in
type 1 diabetes. There were very few babies born in this
weight category (n = 78), with potential for overestimation
of risk, but we think this is unlikely given similar increased
risk seen in general obstetric populations [3]. In the general
obstetric population, LGA infants are also at higher risk, par-
ticularly when weight is above the 95th centile [28]. This was
demonstrated in women with type 2 diabetes but less apparent
in type 1 diabetes. Routine obstetric care for women with
diabetes recommends regular growth scans from 28 weeks
of gestation to help identify at-risk pregnancies and allow
earlier delivery where appropriate [29]. Given this likely pat-
tern of obstetric intervention, similar rates of stillbirth in those
at higher weights may represent some success of these poli-
cies. Birthweights of babies who were stillborn were similar to
live births in type 1 and type 2 diabetes. We lack data on
antenatal growth measures and have used birthweight as the
only available measure to us to explore whether risk is pre-
dominantly in one growth group or another. Further, we accept
that birthweight may underestimate fetal growth in the still-
birth group as it may have reduced or stopped prior to deliv-
ery. Fetal overgrowth relates to maternal hyperglycaemia in
later pregnancy. However, it is notable that even in the sub-
group of women with HbA1c in the lowest quartiles pre-
pregnancy (<52 mmol/mol [<6.9%]) and in the third trimester
(<42 mmol/mol [6%]) birthweight remained considerably
above that of the background population in both type 1 and
2 diabetes.
Optimal timing of delivery in diabetes remains controversial.
In Scotland, routine delivery is recommended between 38 and
40 weeks, while the American College of Obstetricians and
Gynecologists suggests delivery in the 39th week [29, 30], with
individualised assessment for earlier delivery in those with ad-
ditional risk factors. Recent National Institute for Health and
Care Excellence (NICE) guidelines suggest earlier delivery dur-
ing the 37th or 38th week, expedited for those with maternal
and fetal complications [31]. In two prior series from the UK,
RR of stillbirth in women with diabetes compared with the
background population was increased at all stages of pregnancy
[6, 32], but specifically at least fivefold at term [6, 32]. A third
of the stillbirths in this study occurred at term, the majority of
which would be expected to be antepartum rather than
intrapartum. While it is facile to observe that earlier delivery
might avoid these, it has to be balanced against increased risk of
complications such as neonatal respiratory distress syndrome
(RDS) [7]. We could speculate using these data that routine
delivery of our population at 37 weeks would have resulted in
approximately 142 cases of RDS with potential prevention of
22 stillbirths in type 1 diabetes (resulting in stillbirth rate 10.3
per 1000 births), and 72 cases of RDSwith potential prevention
of 12 stillbirths in type 2 diabetes (stillbirth rate 15.5 per 1000
births). However, the increased risk of neonatal morbidity
would need to be more formally explored before recommenda-
tions for optimal timing of delivery are made, especially con-
sidering the very low representation of mothers with diabetes in
current studies [7]. This balance will also be different in indi-
viduals achieving near normoglycaemia. For stillbirths occur-
ring preterm, earlier delivery is less likely to prevent them until
more accurate methods of predicting risk become available.
Others have suggested marked clinic-to-clinic variation
in delivery of care to women with diabetes in pregnancy
[33]. In Scotland, almost all care is organised in multidis-
ciplinary clinics based in secondary (hospital) care. While
units are of differing sizes, stillbirth rates do not appear
significantly different. While accepting limitations of the
power of our study, this is reassuring. There is slight var-
iation in gestational age at delivery and birthweight, which
may reflect migration of complex cases to larger centres for
delivery, but may also indicate variation in obstetric prac-
tice relating to timing of delivery.
It was unexpected that male infants were much more likely
to be stillborn in type 2 diabetes. Male fetuses are more vul-
nerable in utero, with risk moderately increased by 10% [34].
Yet our rates are fourfold higher in male infants than in fe-
males for type 2 diabetes (36.3 per 1000 male births vs 8.8 per
1000 female births). Male fetuses have higher metabolic de-
mand in the later stages of pregnancy yet have smaller pla-
centas than females, which may mean less compensatory re-
serve [35, 36]. Perhaps the combination of a vulnerable pla-
centa and increased metabolic demand of the male infant ex-
plains this higher prevalence.
We have major strengths from robust, whole-population
data that avoid selection bias but acknowledge shortcomings.
First, these are observational data from a population in whom
interventions, such as earlier delivery, will have occurred.
Second, HbA1c was only available in 50–60% of our popula-
tion. After 2006–2008, this would have been from DCCT-
aligned laboratories but there may have been greater variation
between laboratories before this. HbA1c may not always be
measured in later pregnancy as it becomes a less robust cor-
relate of maternal blood glucose level in second and third
trimesters, and is not always routinely recommended [29,
37]. At the same time, our glycaemic results complement
other studies [5, 27, 38, 39]. Third, we lack information across
the whole of the study on important risk factors including
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microvascular complications. Nephropathy increases risk of
IUGR and stillbirth [5, 40]. Methodologies for detecting mi-
crovascular renal disease (e.g. albuminuria) changed over the
audit period in our population, limiting our ability to accurate-
ly report prevalence for the whole time course of the study.
Information on BMI in early pregnancy and gestational
weight gain is also lacking and would be of interest.
Prescription information has only become robustly available
in later years of the study. Folic acid supplementation is rou-
tinely recommended and would be of great interest, along with
exposure to potentially teratogenic drugs. Finally, preeclamp-
sia is a risk factor for IUGR and stillbirth [41–43].
Preeclampsia is known to be underreported in these routine
data, and consistent with this it affects 6.1% of our type 1
diabetes and 4.5% of our type 2 diabetes cohorts, which is
substantially lower than other population estimates [44].
In conclusion, maternal blood glucose level and BMI are
the main modifiable risk factors associated with stillbirth in
our population of women with diabetes. However, there is
significant overlap in values between live and stillborn groups
making it difficult to predict exactly which pregnancies will
end in stillbirth. Achievement of near normoglycaemia re-
mains key to reducing risk. Methods of supporting women
to improve blood glucose levels in pregnancy along with
programmes to optimise weight before pregnancy may help
reduce stillbirth rates but are often challenging to implement
successfully. Mortality risks are highest in infants born SGA,
but large infants are also at increased risk. Stillbirth rate re-
mains high at term in women with diabetes in our population,
and until more accurate prediction of at-risk pregnancies is
available, earlier delivery may be considered an attractive
option.
Acknowledgements We wish to thank the members of the Scottish
Diabetes Research Network Epidemiology Group who are involved in
data provisioning and data quality for this and other projects involving the
national diabetes dataset. The Scottish Diabetes Group Pregnancy sub-
group is a multidisciplinary group involved in the care of women with
diabetes in pregnancy; we acknowledge their contribution to the data,
particularly in data provisioning and clinical care. We also acknowledge
the mothers with diabetes in Scotland.We also wish to thank the Glasgow
Children’s Hospital Charity who fund S.T. Mackin’s clinical research
fellowship.
Data availability Due to the confidential nature of clinical records, our
data are not available in the public domain. SDRN Epidemiology Group
have developed a series of algorithms refining pseudonymised datasets
provisioned by ISD Scotland and can be contacted for collaboration.
Funding The SDRN Epidemiology Group receives financial support
from the Chief Scientists Office of the Scottish Government. Glasgow
Children’s Hospital Charity fund STM’s clinical research fellowship.
Duality of interest HMChas received research support and honoraria and
is a member of advisory panels for Sanofi Aventis, Regneron, Novartis
Pharmaceuticals, Novo-Nordisk and Eli Lilly. HMC has received re-
search support from Pfizer and AstraZeneca LP and is a shareholder of
Roche Pharmaceuticals and Bayer. RSL has acted on advisory boards for
NovoNordisk, Eli Lilly and Servier. These authors have no conflict of
interest in presentation of this manuscript. There are no conflicts of inter-
est from the other authors.
Contribution statement STM and RSL contributed to study concept and
design. RSL, SMN, HMC, SHW and RW helped with data acquisition
and STM and RSL were responsible for data analysis. All authors con-
tributed to data interpretation. STMandRSL prepared themanuscript. All
authors had significant input to revising the manuscript and approving the
final version. RSL is the guarantor of this work.
Scottish Diabetes Research Network EpidemiologyGroup: S. Gribble, A.
Abubaker, A. Barnett, C. Fischbacher, E. Pearson, G. Leese, J. Chalmers,
J. Mcknight, J. Petrie, N. Sattar, O. Wu, R. McCrimmon, S. Philip, S.
Cunningham.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Mackin ST, Nelson SM, Kerssens JJ et al (2018) Diabetes and
pregnancy: national trends over a 15 year period. Diabetologia
61(5):1081–1088. https://doi.org/10.1007/s00125-017-4529-3
2. Feig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe
LL (2014) Trends in incidence of diabetes in pregnancy and serious
perinatal outcomes: a large, population-based study in Ontario,
Canada, 1996–2010. Diabetes Care 37(6):1590–1596. https://doi.
org/10.2337/dc13-2717
3. Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A
(2013)Maternal and fetal risk factors for stillbirth: population based
study. BMJ 346:f108. https://doi.org/10.1136/bmj.f108
4. Flenady V, Koopmans L, Middleton P et al (2011) Major risk fac-
tors for stillbirth in high-income countries: a systematic review and
meta-analysis. Lancet 377(9774):1331–1340. https://doi.org/10.
1016/S0140-6736(10)62233-7
5. Lauenborg J, Mathiesen E, Ovesen P et al (2003) Audit on still-
births in women with pregestational type 1 diabetes. Diabetes Care
26(5):1385–1389. https://doi.org/10.2337/diacare.26.5.1385
6. Tennant PWG, Glinianaia SV, Bilous RW, Rankin J, Bell R (2014)
Pre-existing diabetes, maternal glycated haemoglobin, and the risks
of fetal and infant death: a population-based study. Diabetologia
57(2):285–294. https://doi.org/10.1007/s00125-013-3108-5
7. Stutchfield P, Whitaker R, Russell I, on behalf of the Antenatal
Steroids for Term Elective Caesarean Section Research Team
(2005) Antenatal betamethasone and incidence of neonatal respira-
tory distress after elective caesarean section: pragmatic randomised
trial. BMJ 331(7518):662–662. https://doi.org/10.1136/bmj.38547.
416493.06
8. Scotland ISD (2010) Data quality assurance. Assessment of mater-
nity data 2008–2009. Available from www.isdscotland.org/data_
quality_assurance/DQA-Assessment-of-Maternity-Data-SMR02-
2008-to-2009.pdf. Accessed 31 July 2018
9. Anwar H, Fischbacher CM, Leese G, Lindsay R,McKnight J, Wild
S (2011) Assessment of the under-reporting of diabetes in hospital
admission data: a study from the Scottish diabetes research network
epidemiology group: under-reporting of diabetes in hospital
Diabetologia
admission data. Diabet Med 28(12):1514–1519. https://doi.org/10.
1111/j.1464-5491.2011.03432.x
10. Registration of Births, Deaths and Marriages (Scotland) Act. Sect.
56 (1965)
11. Campbell S, Soothill P (1993) Detection and management of intra-
uterine growth retardation: a British approach. Ultrasound Obstet
Gynecol 2:1432–1435
12. Bonellie S, Chalmers J, Gray R, Greer I, Jarvis S, Williams C
(2008) Centile charts for birthweight for gestational age for
Scottish singleton births. BMC Pregnancy Childbirth 8(1):5.
https://doi.org/10.1186/1471-2393-8-5
13. Scotland ISD (2012) Scottish Index Multiple Deprivation.
Available from: www.isdscotland.org/Products-and-Services/
GPD-Support/Deprivation/SIMD. Accessed 3 June 2019
14. Scotland's Health on the Web (2018) About NHS Scotland.
Available from www.scot.nhs.uk/about-nhs-scotland. Accessed 3
June 2019
15. Pedersen J, Brandstrup E (1956) Foetal mortality in pregnant dia-
betics: strict control of diabetes with conservative obstetric manage-
ment. Lancet 267(6923):607–610. https://doi.org/10.1016/S0140-
6736(56)90649-3
16. Temple R, Aldridge V, Greenwood R, Heyburn P, Sampson M,
Stanley K (2002) Association between outcome of pregnancy and
glycaemic control in early pregnancy in type 1 diabetes: population
based study. BMJ 325(7375):1275–1276. https://doi.org/10.1136/
bmj.325.7375.1275
17. Macintosh MCM, Fleming KM, Bailey JA et al (2006) Perinatal
mortality and congenital anomalies in babies of women with type 1
or type 2 diabetes in England, Wales, and Northern Ireland: popu-
lation based study. BMJ 333(7560):177–177. https://doi.org/10.
1136/bmj.38856.692986.AE
18. Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-
Poulsen T, Damm P (2005) Poor pregnancy outcome in women
with type 2 diabetes. Diabetes Care 28(2):323–328. https://doi.
org/10.2337/diacare.28.2.323
19. Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC
(2005) The pregnancies of women with type 2 diabetes: poor out-
comes but opportunities for improvement. Diabet Med 22(12):
1774–1777. https://doi.org/10.1111/j.1464-5491.2005.01784.x
20. Aune D, Saugstad O, Henriksen T, Tonstad S (2014)Maternal body
mass index and the risk of fetal death, stillbirth, and infant death: a
systematic review and meta-analysis. JAMA 311(15):1536–1546.
https://doi.org/10.1001/jama.2014.2269
21. Ray JG, Vermeulen MJ, Shapiro JL, Kenshole AB (2001) Maternal
and neonatal outcomes in pregestational and gestational diabetes
mellitus, and the influence of maternal obesity and weight gain:
the DEPOSIT* study. QJM 94(7):347–356. https://doi.org/10.
1093/qjmed/94.7.347
22. Yang W, Han F, Gao X, Chen Y, Ji L, Cai X (2017) Relationship
between gestational weight gain and pregnancy complications or
delivery outcome. Sci Rep 7(1):12531. https://doi.org/10.1038/
s41598-017-12921-3
23. Yao R, Park BY, Foster SE, Caughey AB (2017) The association
between gestational weight gain and risk of stillbirth: a population-
based cohort study. Ann Epidemiol 27(10):638–644.e631. https://
doi.org/10.1016/j.annepidem.2017.09.006
24. Instiute of Medicine (2009) Weight gain during pregnancy:
reexamining the guidelines. National Academies Press (US),
Washington (DC)
25. Bell R, Glinianaia SV, Tennant PWG, Bilous RW, Rankin J (2012)
Peri-conception hyperglycaemia and nephropathy are associated
with risk of congenital anomaly in women with pre-existing diabe-
tes: a population-based cohort study. Diabetologia 55(4):936–947.
https://doi.org/10.1007/s00125-012-2455-y
26. Rackham O, Paize F, Weindling AM (2009) Cause of death in
infants of women with pregestational diabetes mellitus and the
relationship with glycemic control. Postgrad Med 121(4):26–32.
https://doi.org/10.3810/pgm.2009.07.2026
27. Edwards A, Springett A, Padfield J, Dorling J, Bugg G, Mansell P
(2013) Differences in post-mortem findings after stillbirth in wom-
en with and without diabetes. Diabet Med 30(10):1219–1224.
https://doi.org/10.1111/dme.12272
28. Contag S, Brown C, Crimmins S, Goetzinger K (2016) Influence of
birthweight on the prospective stillbirth risk in the third trimester: a
cross-sectional cohort study. AJP Rep 6:e287–e298
29. Scottish Intercollegiate Guidelines Network (2010) (March 2010
[updated November 2017]) SIGN 116. Management of diabetes.
Available at www.sign.ac.uk/assets/sign116.pdf. Accessed 3
June 2019
30. American College of Obstetricians and Gynecologists (2005)
ACOG practice bulletin number 60: Pregestational diabetes
mellitus. Obstet Gynecol 105:675–685
31. National Institute for Health and Care Excellence (2015) Diabetes
in pregnancy: management from preconception to the postnatal
period. Available from www.nice.org.uk/guidance/ng3. Accessed
5 July 2019
32. Holman N, Bell R, Murphy H, Maresh M (2014) Women with pre-
gestational diabetes have a higher risk of stillbirth at all gestations
after 32 weeks. Diabet Med 31(9):1129–1132. https://doi.org/10.
1111/dme.12502
33. Murphy HR, Bell R, Cartwright C et al (2017) Improved pregnancy
outcomes in women with type 1 and type 2 diabetes but substantial
clinic-to-clinic variations: a prospective nationwide study.
Diabetologia 60(9):1668–1677. https://doi.org/10.1007/s00125-
017-4314-3
34. Mondal D, Galloway TS, Bailey TC, Mathews F (2014) Elevated
risk of stillbirth in males: systematic review and meta-analysis of
more than 30 million births. BMC Med 12(1):220. https://doi.org/
10.1186/s12916-014-0220-4
35. Eriksson JG, Kajantie E, Osmond C, Thornburg K, Barker DJP
(2010) Boys live dangerously in the womb. Am J Hum Biol
22(3):330–335. https://doi.org/10.1002/ajhb.20995
36. Dearden L, Bouret SG, Ozanne SE (2018) Sex and gender differ-
ences in developmental programming of metabolism. Mol Metab
15:8–19. https://doi.org/10.1016/j.molmet.2018.04.007
37. Hughes RCE, Rowan J, Florkowski CM (2016) Is there a role for
HbA1c in pregnancy? Curr Diab Rep 16(1):5. https://doi.org/10.
1007/s11892-015-0698-y
38. Mathiesen ER, Ringholm L, Damm P (2011) Stillbirth in diabetic
pregnancies. Best Pract Res Clin Obstet Gynaecol 25(1):105–111.
https://doi.org/10.1016/j.bpobgyn.2010.11.001
39. Mathiesen ER (2016) Pregnancy outcomes in women with
diabetes—lessons learned from clinical research: the 2015
Norbert Freinkel award lecture. Diabetes Care 39(12):2111–2117.
https://doi.org/10.2337/dc16-1647
40. Ekbom PIA, Damm P, Feldt-Rasmussen BO, Feldt-Rasmussen U,
Molvig J, Mathiesen ER (2001) Pregnancy outcome in type 1 dia-
betic women with microalbuminuria. Diabetes Care 24(10):1739–
1744. https://doi.org/10.2337/diacare.24.10.1739
41. Duley L (2009) The global impact of pre-eclampsia and eclampsia.
Semin Perinatol 33(3):130–137. https://doi.org/10.1053/j.semperi.
2009.02.010
42. Persson M, Norman M, Hanson U (2009) Obstetric and perinatal
outcomes in type 1 diabetic pregnancies. A large, population-based
study. Diabetes Care 32(11):2005–2009. https://doi.org/10.2337/
dc09-0656
43. Dunne F, Brydon P, Smith K, Gee H (2003) Pregnancy in women
with type 2 diabetes: 12 years outcome data 1990–2002. Diabet
Med 20(9):734–738. https://doi.org/10.1046/j.1464-5491.2003.
01017.x
Diabetologia
44. Roberts CL, Ford JB, Algert CS et al (2011) Population-based
trends in pregnancy hypertension and pre-eclampsia: an interna-
tional comparative study. BMJ Open 1:e000101
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia
